Clearmind Medicine (CMND) announced Wednesday that its independent Data and Safety Monitoring Board has completed its review and issued a positive recommendation to continue the ongoing FDA-approved Phase I/IIa clinical trial of CMND-100 for the treatment of Alcohol Use Disorder. The DSMB recommendation follows the completion of the third cohort and is based on encouraging top-line safety data demonstrating that CMND-100 was well tolerated with no serious adverse events reported. These results reinforce the favorable safety and tolerability profile observed in previous cohorts. As a result, the Company will now proceed to the fourth cohort of the trial and will increase the tested dose of its proprietary drug candidate CMND-100 to 160mg.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Morning Movers: Globalstar climbs following deal to be acquired by Amazon
- Clearmind Medicine announces CMND-100 meets primary endpoint
- Psychedelic: Clearmind completes treatment, follow-up for CMND-100 trial
- Clearmind Medicine completes treatment, follow-up in CMND-100 trial
- Clearmind files patent application in India for psychedelic-based compounds